» Articles » PMID: 36568337

Chronic Eosinophilic Leukemia Presenting As Cardiac Failure

Overview
Publisher Wiley
Specialty Hematology
Date 2022 Dec 26
PMID 36568337
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic eosinophilic leukemia (CEL) is a rare chronic myeloproliferative disorder characterized by sustained eosinophilia. Although the incidence of CEL is uncertain, it can be clinically devastating as it has a propensity to affect several important organ systems. This is of particular significance in Sub-Saharan Africa where helminthic infections are a more prevalent cause of eosinophilia. To the best of our knowledge, we present the first reported case of CEL complicated by cardiac disease in a Ghanaian. He presented with a history of orthopnoea and dyspnoea on exertion, and examination revealed a pansystolic murmur over the mitral region and moderate splenomegaly. Good symptomatic control was achieved using hydroxyurea after which haematologic and cytogenetic remission was achieved after 12 weeks on a tyrosine kinase inhibitor. Physicians working in low resource environments should exclude clonality in patients presenting with eosinophilia and end-organ damage.

Citing Articles

Eosinophilic Myocarditis Resulting in Ventricular Tachycardia Storm.

Hengst D, Kandah D, Dervesh R, Ellerman M, Ugwu J, Goerbig-Campbell J Cureus. 2024; 16(3):e56779.

PMID: 38650811 PMC: 11034619. DOI: 10.7759/cureus.56779.

References
1.
Cools J, DeAngelo D, Gotlib J, Stover E, Legare R, Cortes J . A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348(13):1201-14. DOI: 10.1056/NEJMoa025217. View

2.
Cogan E, Schandene L, Crusiaux A, Cochaux P, Velu T, Goldman M . Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med. 1994; 330(8):535-8. DOI: 10.1056/NEJM199402243300804. View

3.
Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S . The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica. 2007; 92(9):1173-9. DOI: 10.3324/haematol.11420. View

4.
Pardanani A, Brockman S, Paternoster S, Flynn H, Ketterling R, Lasho T . FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004; 104(10):3038-45. DOI: 10.1182/blood-2004-03-0787. View

5.
Qu S, Qin T, Xu Z, Zhang Y, Ai X, Li B . Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China. Oncotarget. 2016; 7(22):33229-36. PMC: 5078089. DOI: 10.18632/oncotarget.8906. View